Peter Jarrett

Chief Scientific Officer

Professional Overview
Peter Jarrett is a renowned scientist and industry leader with over 35 years of experience in the pharmaceutical and biotechnology sectors. As the Chief Scientific Officer at Ocular Therapeutix, he is responsible for driving the company's research and development efforts, with a focus on innovative ocular drug delivery solutions.

Experience Summary

Current Role
As the Chief Scientific Officer at Ocular Therapeutix, Peter is spearheading the company's research and development initiatives, overseeing the design, development, and testing of novel ophthalmic drug delivery platforms. Under his leadership, Ocular Therapeutix has made significant strides in advancing its pipeline of innovative therapies, with several products in various stages of clinical development.

Career Progression
Prior to joining Ocular Therapeutix, Peter held various leadership positions in the industry, including serving as the VP of Biomaterials R&D at Genzyme, where he played a pivotal role in the development of the company's biomaterial-based drug delivery technologies. He also served as the VP of R&D at Focal Inc., a company focused on the development of sealant and adhesive technologies for surgical applications. Earlier in his career, Peter held research roles at Davis & Geck, American Cyanamid, and Aerojet, where he contributed to the advancement of chemical and material science innovations.

Academic Background
Peter holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology (MIT), where he specialized in the development of novel polymeric materials and their applications in biomedical engineering.

Areas of Expertise

• Expertise in the design and development of drug delivery systems, with a focus on ophthalmic applications

• Extensive knowledge of biomaterials, polymer science, and material engineering

• Proven track record in leading cross-functional teams and driving innovative research programs

• Exceptional problem-solving skills and ability to translate scientific insights into commercially viable products

Professional Impact
Under Peter's leadership, Ocular Therapeutix has made significant strides in advancing its pipeline of innovative ocular therapies, with several products currently in various stages of clinical development. His contributions have been instrumental in positioning the company as a leader in the field of ophthalmic drug delivery.

Conclusion
With his deep scientific expertise, extensive industry experience, and proven track record of driving innovation, Peter Jarrett is a valuable asset to Ocular Therapeutix. As the Chief Scientific Officer, he continues to push the boundaries of what's possible in the field of ophthalmic drug delivery, positioning the company for long-term success and improved patient outcomes.